The in Vivo Toxicity of Hydroxyurea Depends on Its Direct Target Catalase

Abstract excerpt

Hydroxyurea (HU) is a well tolerated ribonucleotide reductase inhibitor effective in HIV, sickle cell disease, and blood cancer therapy. Despite a positive initial response, however, most treated cancers eventually progress due to development of HU resistance. Although RNR properties influence HU resistance in cell lines, the mechanisms underlying cancer HU resistance in vivo remain unclear. To address this...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Hemoglobinopathies and Related Disorders
• Share to Liver Disease and Transplantation
• Share to Pregnancy and preeclampsia studies